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The European Partnership for Alternative Approaches to Animal Testing (EPAA) convened a Partners' 60 
Forum on repeated dose toxicity (RDT) testing to identify synergies between industrial sectors and 61 
stakeholders along with opportunities to progress these in existing research frameworks.  Although 62 
RTD testing is not performed across all industrial sectors, the OECD accepted tests can provide a rich 63 
source of information and play a pivotal role for safety decisions relating to the use of chemicals. 64 
Currently there are no validated alternatives to repeated dose testing and a direct one-to-one 65 
replacement is not appropriate. However, there are many projects and initiatives at the international 66 
level which aim to implement various aspects of replacement, reduction and refinement (the 3Rs) in 67 
RDT testing. Improved definition of use, through better problem formulation, aligned to 68 
harmonisation of regulations is a key area, as is the more rapid implementation of alternatives into 69 
the legislative framework. Existing test designs can be optimised to reduce animal use and increase 70 
information content. Greater use of exposure-led decisions and improvements in dose selection will 71 
be beneficial. In addition, EPAA facilitates sharing of case studies demonstrating the use of Next 72 
Generation Risk Assessment applying various New Approach Methodologies to assess RDT.   73 
 74 
 75 
Keywords:  Repeated dose toxicity testing; alternatives; safety assessment; chemical legislation; in 76 
vitro; in silico; Threshold of Toxicological Concern (TTC); cross-sector; Integrated Approaches for 77 
Testing and Assessment (IATA); Weight of Evidence (WoE) 78 
  79 
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Highlights  80 
 81 
 RDT tests are information rich and pivotal for safety assessment in many sectors 82 
 Direct replacement of RDT tests by non-animal approaches is not currently possible or 83 
appropriate 84 
 New Approach Methodologies can assist in safety decisions on systemic toxicity 85 
 Refinements and improvements to RDT tests could reduce and optimise animal use 86 
 There is a need to share data, information and methodologies across sectors 87 
  88 
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1. Introduction 111 
This report describes the main findings and conclusions of The European Partnership for Alternative 112 
Approaches to Animal Testing (EPAA) Partners’ Forum on the topic of repeated dose toxicity (RDT) 113 
testing, held on 19 November 2018 in Brussels, Belgium. The EPAA Partners’ Forum aimed to identify 114 
synergies between industrial sectors and stakeholders along with opportunities to progress these in 115 
existing research and testing frameworks. The EPAA Partners’ Forum brought together 36 participants 116 
from industry and European Commission (EC), along with invited representatives from regulatory 117 
agencies and researchers from a large EU-funded project.  118 
The invited participants represented the EC Directorates-General (DGs) Environment (ENV); Internal 119 
Market, Industry, Entrepreneurship and SMEs (GROW); Joint Research Centre (JRC); and Research and 120 
Innovation (RTD); the European Chemicals Agency (ECHA); the European Food Safety Authority (EFSA); 121 
the German Federal Institute for Drugs and Medical Devices (also as representative of the European 122 
Medicines Agency (EMA)); as well as companies from the chemicals, pharmaceuticals and vaccines, 123 
cosmetics, soaps and detergents, crop protection, animal health and fragrances sectors and their 124 
European trade associations and representatives from key EC funded projects relevant for this topic. 125 
Hans Bender (Germany) chaired the Partners' Forum and moderated the discussions. 126 
It should be noted that this report is based on the presentations and actual discussions at the EPAA 127 
Partners’ Forum aiming to achieve the stated objectives of the event. These focussed on the 128 
possibilities of each of the 3Rs (replacement, reduction and refinement of animal testing), to different 129 
extents, to be used in RDT testing as well as for the overall mission of ensuring human safety. It should 130 
not be considered a complete or comprehensive review of research efforts or potential synergies in 131 
the area of RDT testing. 132 
 133 
1.1 Definitions and Context 134 
For the purposes of this report, the term “RDT testing” is assumed in its broadest context and across 135 
as wide a group of industries and use scenarios as possible. The EPAA Partners’ Forum acknowledged 136 
that there are a variety of “standard” Organisation for Economic Co-operation and Development 137 
(OECD) RDT tests which range from 28 to 90 days and longer (up to 2 years duration in rodent and 138 
non-rodent species). The main tests for regulatory use are summarised in Table 1. RDT tests are 139 
considered to be studies that are designed to evaluate a wide range of effects in vivo upon prolonged 140 
exposure. As such, RDT testing provides information on the potential profile of toxicity in animals that 141 
can be used in the context of defining safety in humans. In addition, information from RDT testing may 142 
trigger additional investigations for reproductive toxicity, immunotoxicity, neurotoxicity or 143 
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carcinogenicity. There is an historical assumption that current RDT tests in animals are predictive of 144 
effects on human health, although interspecies variability (which may reveal lack of relevance) is 145 
acknowledged when using such data for safety assessments in humans. As such, in many sectors, 146 
despite the potential limitations, the results from RDT tests are one of the cornerstones of ensuring 147 
safety of consumers, patients and for occupational exposure.  148 
 149 
 150 
Table 1. Summary of the key standard tests and OECD Test Guideline studies for repeated dose 151 
toxicity  152 
 153 
Short-term repeated dose toxicity study (28-day) 154 
 Repeated Dose 28-day Oral Toxicity Study in Rodents (OECD 407) 155 
 Combined Repeated Dose Toxicity Study with the Reproduction/ Developmental Toxicity 156 
Screening Test (OECD 422) 157 
 Subacute Inhalation Toxicity: 28-Day Study (OECD 412) 158 
 Repeated Dose Dermal Toxicity: 21/28-day Study (OECD 410) 159 
Sub-chronic toxicity study (90-day) 160 
 Repeated Dose 90-Day Oral Toxicity Study in Rodents (OECD 408) 161 
 Subchronic Inhalation Toxicity: 90-day Study (OECD 413) 162 
 Subchronic Dermal Toxicity: 90-day Study (OECD 411) 163 
Long-term repeated dose toxicity studies  164 
 Chronic toxicity studies (OECD 452) primarily in rodents 165 
 Combined chronic toxicity/carcinogenicity studies (OECD 453), typically tested in rats 166 
 167 
 168 
Whilst the use of many standard tests of varying exposure time was acknowledged, the EPAA Partners’ 169 
Forum focussed much of its attention on the 90-day assays – at the same time appreciating that these 170 
tests are not performed in the cosmetics industry. Typically the 90-day RDT test requires two species 171 
and an appropriate route of exposure, most commonly oral, but dermal and inhalation may also be 172 
required. Dosing at a range of concentrations up to the maximum tolerated dose is performed 173 
regularly, e.g. daily, and observations are compared to a control. The observations should include 174 
clinical, histopathological, behavioural and many other measurements. Testing may also include 175 
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range-finding and palatability studies, usually of short duration. Observations of endpoints in RDT test 176 
may trigger further testing for specific effects. Details of experimental design and procedures are 177 
provided in the Test Guidelines referred to in Table 1 although there are many variations and 178 
additional requirements as summarised below.  179 
The EPAA Partners’ Forum heard that, with the exception of the cosmetics industry, RDT testing is 180 
commonly performed across all industrial sectors. It is considered to provide a rich source of data and 181 
information on the effects of a chemical on an organism. Industrial sectors such as pharmaceutical, 182 
crop protection and biocides have considerable expertise in RDT testing with a relatively 183 
comprehensive inventory of historical data. In the case of pharmaceuticals, the safety assessment of 184 
a new drug may also be supported by human data. As such, the results of RDT testing, especially the 185 
90-day test, are currently pivotal to many industries to ensure safety of products to humans.  186 
 187 
1.2 Regulatory Importance, Status and Challenges of RDT Testing 188 
The EPAA Partners’ Forum heard that the use of RDT testing is governed by a multitude of regulations, 189 
directives and guidelines. The regulations cover different industrial sectors and global regions and it is 190 
inevitable that there are different requirements within individual sectors and geographies, those 191 
presented at the Forum are summarised briefly below. However, at the core of all regulations is the 192 
recognition of the use of OECD Test Guideline studies, mostly due to Mutual Acceptance of Data within 193 
and outside of OECD countries. The 90-day RDT test is frequently required due to the depth of 194 
information it provides and the understanding of the results. As well as being a regulatory information 195 
requirement, the results of RDT testing for the most sensitive species and endpoint can be used to 196 
identify points of departure (PoD), notably the No Observed (Adverse) Effect Level (NO(A)EL), Lowest 197 
Observed (Adverse) Effect Level (LO(A)EL) and, where possible, benchmark dose (BMD). The PoD can 198 
then be used in a safety context e.g. to set the reference doses for non-dietary safety evaluation or 199 
Acceptable Daily Intake (ADI) for dietary exposure assessment. In addition, the information from the 200 
90-day RDT test can inform regulatory decisions such as classification and labelling and identification 201 
of specific hazards that may require further investigation.  202 
Even within a single geographical area, there are a large number of regulations covering the various 203 
types and uses of chemicals. For instance, the European Union (EU) has various regulations covering 204 
different topics including industrial chemicals, cosmetics products, plant protection active ingredients 205 
biocidal active ingredients and related products. In addition, other regulations such as for 206 
pharmaceuticals and activities such as Community Strategies on Endocrine Disruptors and Combined 207 
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Exposures to Mixtures (European Commission, 1999) need to be taken into account. The result is a 208 
variety of requirements, some of which may even be considered contradictory with each other.  209 
Further information was provided to the EPAA Partners’ Forum relating to the role of individual 210 
European Agencies in using information from RDT tests. Under the Registration, Evaluation, 211 
Authorisation and restriction of CHemical substances (REACH) regulation, the European Chemicals 212 
Agency (ECHA) has minimum requirements for data dependent on tonnage and other conditions. 213 
However, ECHA’s database which is available through ECHA’s dissemination portal (cf. 214 
https://echa.europa.eu/information-on-chemicals) has many data gaps for RDT studies and, with the 215 
aim of avoiding as much animal testing as possible, the REACH regulation allows for adaptation of 216 
standard information requirements e.g. by using alternatives such as read-across. The European Food 217 
Safety Authority (EFSA) recognises the critical role of the 90-day study as a data requirement in six 218 
types of regulated products (i. food packaging and contact materials, ii. food ingredients, iii. feed 219 
additives, iv. genetically modified organisms, v. dietetic products, nutrition and food allergies, novel 220 
foods, and vi. pesticides). Within the data requirements, the 90-day study may be used differently, 221 
e.g. it is required by default for pesticides and as part of a tiered approach for food contact materials.  222 
RDT studies are particularly valuable to the pharmaceutical industry to support clinical drug 223 
development in both Phase 1 and Phase 2. For pharmaceuticals, under the ICH M3(R2) regulations in 224 
the EU, there are generally differences in RDT studies for small molecules and biologicals. There is 225 
strong evidence of international collaboration e.g. between the EU, USA and elsewhere through the 226 
acceptance of a number of pieces of legislation from the International Conference on Harmonisation 227 
of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).  228 
For cosmetics ingredients, since March 2013 there has been a full ban on animal testing in the EU with 229 
several other countries also imposing a ban – raising a strong possibility that this may become a global 230 
ban. Despite the ban, it is emphasised by Cosmetics Europe that there is a need for information 231 
regarding systemic toxicity. However, with regard to regulatory submissions to e.g. the EC’s Scientific 232 
Committee on Consumer Safety (SCCS), it is recognised that several test methods and guidelines for 233 
endpoints relating to RDT exist but acceptance of non-animal tests for systemic toxicity to assure 234 
safety is not guaranteed.  235 
The EPAA Partner’s Forum identified a number of challenges relating to the regulatory use and 236 
acceptance of RDT testing and specifically the implementation of alternatives and the 3Rs: 237 
- There is a very slow pace of change in regulatory acceptance of updates to RDT testing, 238 
specifically relating to the replacement (and to a lesser extent refinement) of in vivo tests and 239 
understanding and implementing the best new technology and innovation.  240 
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- There is a lack of harmonisation and consistency in the data requirements in regulations 241 
between sectors and also between regions.  242 
- There is varied, but often limited, implementation of alternatives to RDT testing in regulatory 243 
toxicology of which none are validated as a full replacement. Some sectors, however, are 244 
creating an environment to implement alternatives e.g. the International Cooperation on 245 
Cosmetics Regulation (ICCR) Principles for new methodologies in the risk assessment of 246 
cosmetic ingredients (Dent et al., 2018). 247 
- There is a lack of coherent and transferable data resources for e.g. the in vivo tests and also 248 
the alternatives. Such resources could ensure that testing is not repeated unnecessarily and 249 
could assist with the validation of alternatives. In addition, retrospective studies of data can 250 
assist in the refinement of existing tests. 251 
The challenges for the use of 3Rs in RDT for regulatory purposes were considered by the EPAA 252 
Partners’ Forum and the initiatives attempting to address them are discussed in Section 2 along with 253 
opportunities in Section 3 below.  254 
 255 
1.3 Impact of the 3Rs and other Alternatives on RDT 256 
The EPAA Partners’ Forum concluded that whilst there are currently no valid or validated non-animal 257 
alternatives that replace RDT tests directly, there is increasing use of alternatives in decision making 258 
e.g. for exposure-driven risk assessment in the cosmetics industry. Further, despite it being highly 259 
unlikely that a direct and complete one-to-one replacement of RDT testing will be possible, dependent 260 
on context, (non-validated) alternatives and different approaches are being increasingly applied to 261 
assist in safety decision making e.g. in the cosmetics industry. The lack of validated alternatives is due 262 
to the complexity of the RDT endpoint and the wealth of information that it provides on organ level 263 
and many other effects as well as the nature of the current validation paradigm. The information 264 
provided from the current RDT tests is, at present, essential in many industry sectors to assuring 265 
human safety.  266 
Whilst the EPAA Partners’ Forum acknowledged the lack of any suitable direct alternatives to RDT 267 
testing, there was unanimous support for greater effort in their development, implementation and 268 
acceptance. There are many drivers for these alternatives including ethical concerns, but also to 269 
provide better and more human-relevant safety information and to fill gaps in toxicological 270 
knowledge. In the context of the 3Rs, all aspects of alternatives were considered by the EPAA Partners’ 271 
Forum including knowledge of exposure as well as knowledge from New Approach Methodologies 272 
11 
 
(NAMs) encompassing in chemico and in vitro assays, omics technologies (e.g. metabolomics and 273 
transcriptomics) and in silico approaches. In addition to the methodologies, strategies for their 274 
implementation and acceptance were discussed, as well as potential improvements (e.g. refinements) 275 
to existing RDT tests that could enhance the knowledge gained. Details on current projects and 276 
initiatives to develop and implement the 3Rs and alternatives to RDT testing are provided in Section 277 
2.  278 
 279 
2. Initiatives, Projects and Current Use of Alternatives for RDT   280 
Many initiatives and funded projects in the area of RDT that have attempted to develop alternatives 281 
were described in the EPAA Joint Partners’ Forum, these are summarised in Table 2 with a broader 282 
discussion of their relevance given below. It is however recognised in this report that others exist and 283 
may not be mentioned herein.  284 
 285 
Table 2. Summary of main initiatives and projects relating to the development and increased 286 
acceptance of non-animal approaches for repeated dose toxicity testing (RDT) discussed at the EPAA 287 
Partners’ Forum. Further details are available from the reference provided.  288 
Initiative or Project Funding 
agency, 
organiser etc 
More information  
   
Funded Projects    

















Daneshian et al. (2016); http://www.eu-toxrisk.eu/ 
Accelerating the 
















of RDT project 





(example of RDT 










Feasibility study on 
data sharing  
European 
Parliament 
European Parliament (2018) 




Farmahin et al. (2017) 
Microphysiological 
Systems Program 
FDA, NIH Wikswo et al. (2013) 




   
FDA Roadmap US FDA US FDA (2017) 
EMA identified 
alternatives 
EMA EMA (2019a, 2019b) 
Map of RDT 
Mechanisms  
JRC Prieto et al. (2014, 2019) 
Project proposal for 
a Blue-sky 
workshop: Soliciting 
input for new ideas 
to address repeated 
dose toxicity 
EPAA https://ec.europa.eu/growth/sectors/chemicals/epaa_en 
   
Workflows   
   
SEURAT-1 Workflow EC / Cosmetics 
Europe 
Berggren et al. (2017); OECD (2017) 
LRSS Workflow Cosmetics 
Europe 




RIFM  Api et al. (2015) 
ICCR Principles ICCR Dent et al. (2018) 
   
 289 
 290 
2.1 European Union (EU) Funded Projects 291 
The EU has provided considerable support through various funding schemes for research into animal-292 
free toxicology. Since 1998 (the Fifth Framework Programme, FP5) until the current time (Horizon 293 
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2020, H2020) the EU has funded over 200 international projects with over 700€ million, with funding 294 
increasing with each cycle of Framework Programmes. In addition, over 150€ million has been 295 
provided in support by industry for 3Rs-relveant safety testing (25€ million from Cosmetics Europe for 296 
SEURAT-1; 85€ million and 40€ million from the European pharmaceuticals industry for IMI and IMI2 297 
projects respectively). Over three quarters of the funding has been directed towards mammalian 298 
toxicology, of which a substantial part was devoted to RDT. The contribution of past and on-going EU 299 
projects to the 3Rs was recognised by the EPAA Partners’ Forum and more details were provided on 300 
two of the larger initiatives and projects, as described below.  301 
One of the most significant EU funding initiatives for RDT was “SEURAT-1”. This was a cluster of six 302 
research projects (2011-2015) which ranged from the development of assays from stem cells, to in 303 
vitro biomarkers and a microfluidic bioreactor, coupled to computational models and databases 304 
(Gocht et al., 2015). The SEURAT-1 Workflow, constructed on existing data, in silico modelling and 305 
biokinetic considerations, was one of the most important outputs which aimed to assess chemical 306 
safety without relying on animal testing (Berggren et al., 2015, 2017; OECD, 2017). Whilst the 307 
Workflow was designed with cosmetic ingredients in mind, it is relevant to RDT and applicable to other 308 
chemicals, e.g. pharmaceuticals, plant protection products or biocides, etc. The current EU funded 309 
“flagship” project relating to RDT is EU-ToxRisk (Daneshian et al., 2016). This is a six year (2016-2021), 310 
multidisciplinary project with approximately 30€ million of funding. The aims of EU-ToxRisk are to 311 
develop pragmatic, robust read-across procedures incorporating mechanistic and toxicokinetic 312 
knowledge through the use of case studies. Implementation of alternatives is a key aspect of EU-313 
ToxRisk and it works closely with stakeholders including regulatory authorities (through a Regulatory 314 
Advisory Board) to make the alternatives fit-for-purpose.  315 
 316 
2.2 Industry Funded Projects and Initiatives 317 
The cosmetics industry has a long history of supporting the development of non-animal approaches 318 
to RDT. This has gained increased importance due to the full implementation of a ban on animal testing 319 
for cosmetics ingredients which came into force in the EU in March 2013. Through Cosmetics Europe, 320 
the European cosmetics industry co-funded the SEURAT-1 initiative, as noted above. The SEURAT-1 321 
Workflow proposed by Berggren et al., (2017), became the starting point for Cosmetics Europe’s “Long 322 
Range Science Strategy” (LRSS) programme which included RDT as part of its 2016-2020 framework. 323 
The LRSS has three main goals, namely, to develop relevant non-animal NAMs; to apply and 324 
implement the NAMs in Next Generation Risk Assessments (NGRAs); and to ensure NAMs and NGRAs 325 
fit to the regulatory framework. These concepts were expanded upon by Desprez et al., (2018) who 326 
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implemented and extended the SEURAT-1 Workflow into the LRSS. The updated Workflow has 327 
incorporated three tiers to understand risk assessment for systemic toxicity which were extended by 328 
the ICCR who proposed nine principles for using NAMs in (human-relevant) risk assessment (Dent et 329 
al., 2018).  330 
Amongst a significant number of projects funded through the LRSS to develop NAMs and demonstrate 331 
their use for NGRA, two were shown during the EPAA Partners’ Forum as examples of activities 332 
ongoing in the field of RDT. The first example relates to defining an ontology that includes Mode of 333 
Action (MoA) elements for RDT and in which links are made with (internal) exposure and chemistry 334 
(Desprez et al., 2019). The second example introduced at the EPAA Partners’ Forum was the 335 
development of a chemoinformatics platform (CE-ToxGPS). The CE-ToxGPS  platform develops further 336 
the COSMOS database (https://cosmosdb.eu/cosmosdb.v2/) and is intended to extend the role of the 337 
system from data storage to data integration with active workflows and inclusion of predictive 338 
capabilities to help risk assessors. 339 
Related to cosmetic products, the safe use of fragrance materials is ensured by the fragrance 340 
industry’s self-regulatory programme through its members and affiliates IFRA and the Research 341 
Institute for Fragrance Materials (RIFM) Inc, in which scientific data are generated, evaluated and 342 
distributed for the safety of fragrance raw materials found in personal and household care products. 343 
In order to determine safety, a four step procedure with evaluation from an Expert Panel is applied 344 
(Api et al., 2015) and the findings are made available through the Food and Chemical Toxicology 345 
Fragrance Material Safety Assessment Center (RIFM, 2019).  346 
The fragrance industry’s safety evaluation procedure is updated on a regular basis through specific 347 
projects. For instance, to assess aggregate consumer exposure RIFM continues to improve exposure 348 
information through the use and refinement of the Creme RIFM Aggregate Exposure Model 349 
(https://www.cremeglobal.com/products/creme-rifm/; Safford et al., 2017). Computational and 350 
chemistry-based approaches, including read-across, have been used to evaluate the safety of 351 
fragrance materials where there are data gaps, although there is an on-going challenge with the 352 
justification of chemical similarity (which goes beyond the fragrance industry). In addition, the use of 353 
the Threshold of Toxicological Concern (TTC) has had a significant impact on decreasing the need for 354 
in vivo testing, since many fragrance ingredients are only used in very small concentrations  (Bhatia et 355 
al., 2015).  356 
The agrochemicals industry, (in part through the European Crop Protection Association (ECPA)) are 357 
investigating multiple approaches to use omics data e.g. from the study of responses such as RNA 358 
molecules at the transcriptome level or chemical processes involving metabolites at the metabolomic 359 
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level to provide more efficient means of defining PoDs. In this regard industry is working alongside 360 
regulatory agencies e.g. recommendations from a joint United States Environmental Protection 361 
Agency (EPA) and Health Canada study (Farmahin et al., 2017) are being investigated. The 362 
agrochemicals industry has also demonstrated the use of methods such as metabolomics for read-363 
across (van Ravenzwaay et al., 2016) as well as other efforts demonstrating the utility of epigenetics 364 
in safety assessment (LaRocca et al., 2017) and omics technologies in chemical risk assessment 365 
(Buesen et al., 2017). 366 
 367 
2.3 Initiatives from Governmental and Regulatory Agencies 368 
Within Europe a number of agencies have recognised the potential use of alternatives to RDT and are 369 
involved in initiatives to support their implementation. ECHA reported that adaptations to REACH 370 
requirements for RDT commonly include read-across, whilst acknowledging the difficulty in this 371 
approach due to the lack of scientifically sound approaches and justification occurring frequently in 372 
the dossiers. ECHA is also involved in the Accelerating the Pace of Chemical Risk Assessment (APCRA) 373 
project (Kavlock et al., 2018). APCRA was initiated by the United States Environmental Protection 374 
Agency (EPA~) with the aim of bringing together international governmental regulators and 375 
researchers to discuss progress and barriers in applying NAMs to prioritisation, screening, and 376 
quantitative risk assessment of differing levels of complexity. There are a number of (mainly 377 
regulatory) organisations within Europe, USA, Canada and South Korea. Within APCRA, ECHA leads a 378 
case study which aims to provide a qualitative and quantitative comparison of NAMs and traditional 379 
RDT animal toxicity testing for data-poor chemicals.  380 
EFSA also has a number of initiatives to provide information for data-poor substances. These initiatives 381 
cross a number of endpoints but are also relevant to RDT. They include, but are not limited to, the 382 
assessment of, and models for, dermal absorption; the use of QSARs and read-across to make 383 
predictions of effects; the promotion of the use of NAMs for the parent compound and metabolites; 384 
the use of AOPs; and assays for in vitro hepatic metabolism.  385 
The EC’s Joint Research Centre (JRC) has been at the forefront of evaluating the use of alternatives to 386 
in vivo toxicity testing for several decades. A part of applying these techniques has been the use of 387 
Integrated Approaches to Testing and Assessment (IATA) that attempt to integrate and weight all 388 
existing evidence and guide the targeted generation of new data, for the purpose of making regulatory 389 
decisions (OECD, 2016). Previous work from the JRC focussed on the assessment of mammalian acute 390 
toxicity and demonstrated the possibility of identifying and defining the mechanisms and hence 391 
pathways associated with acute oral toxicity (Prieto et al., 2014; 2019). The JRC is proposing to 392 
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undertake an analysis of RDT studies to gather, organise and analyse mechanistic knowledge, 393 
alongside data, related to toxicological effects on target organs in animal models after repeated 394 
exposure to chemicals, i.e. to map out the mechanisms related to RDT. The outcome of this analysis 395 
will be the description of a set of characteristics of chemicals inducing repeated dose systemic toxicity 396 
which will inform the development of alternative approaches and help to enhance standard in vivo 397 
studies to maximise the information they provide. 398 
The EMA supports the use of the 3Rs and alternatives to evaluate the safety of medicinal products 399 
(EMA, 2019a). Through the EMA’s Joint Working Group on the Application of the 3Rs in Regulatory 400 
Testing of Medicinal Products (J3RsWG) it is providing reflection papers and guidelines on the 401 
development of the 3Rs to identify toxicity, including RDT, in addition to recommendations on the 3Rs 402 
for the European Pharmacopoeia (EMA, 2019b). The series of reflection papers (EMA, 2016, 2017, 403 
2018a,b) have provided the context for the use of alternatives for medicinal products. The reflection 404 
document (EMA, 2018b; page 8) provides information on 3Rs opportunities in RDT that are already 405 
implemented and accepted by the regulators.  406 
The US Food and Drug Administration (FDA) aims to integrate emerging predictive technologies in 407 
safety assessment and identify priority challenges. However, it recognises the challenges faced by 408 
regulatory toxicologists in keeping pace with scientific and technological developments, specifically, 409 
the balance of ensuring safety whilst supporting innovation and the need to carefully define the 410 
context of the use of the alternative. The FDA has formed a Senior Toxicologist Working Group 411 
comprising senior toxicologists from all six FDA program Offices in addition to the National Center for 412 
Toxicological Research and the Office of the Commissioner. The purpose of the Working Group is to 413 
share information on new methods in toxicology as well to allow FDA regulatory and research 414 
scientists to become familiar with emerging toxicology tests and their potential usefulness in risk 415 
assessment. The FDA Predictive Toxicology Roadmap (US FDA, 2017) sets out the vision to identify 416 
critical priority activities for the integration of emerging predictive toxicology methods and new 417 
technologies into regulatory risk assessments. The Roadmap is intended to emphasise the context of 418 
use and the “qualification” of a model or assay i.e. whether it can be relied upon to have a specific 419 
interpretation and application in product development and regulatory decision-making for a particular 420 
use. Partnerships are an essential part of the Roadmap – as such the “3Cs” themes run through all the 421 
roadmaps and initiatives, these are Communication, Collaboration and Commitment.  422 
 423 
3. Opportunities for the 3Rs in RDT Testing 424 
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A key objective of the EPAA Partners’ Forum was to identify opportunities to progress the synergies 425 
between industrial sectors to rationalise and improve RDT testing. The key opportunities are 426 
summarised in Table 3. In this section these opportunities are organised into various themes whereby 427 
needs or on-going research in one (or more) sectors could be more broadly applied. The purpose here 428 
is to foster an on-going dialogue and a move towards more synergy and understanding across sectors.  429 
 430 
 431 
Table 3. Key opportunities and needs to implement the 3Rs for RDT testing. Full details are provided 432 
in Section 3.  433 
 Development of common data resources 434 
 Improvement of mechanistic understanding 435 
 Creation of common ontologies to link exposure, kinetics, chemistry, MoA and effects 436 
 Better use of IATA or Weight of Evidence (WoE) strategies 437 
 Incorporation of NAMs or other data to supplement lacking data  438 
 Improvement in validation of NAMs to facilitate acceptance 439 
 Optimisation of RDT in vivo test guidelines 440 
 Harmonisation as far as possible of regulations across sectors and geographies 441 
 Increasing dialogue between stakeholders to increase awareness of new technologies 442 
 Direct projects and case studies to solve specific problems 443 
 Definition and agreement on the information needs that data from RDT tests currently fill in 444 
different industry sectors/different regulatory settings i.e. decision-making context 445 
 446 
 447 
3.1 Raising Cross-Sector Awareness and Collaboration to Define Cross-Sector Opportunities to 448 
Improve, and Ultimately Replace, RDT 449 
The EPAA Partners’ Forum appreciated a key opportunity that underpins much potential progress in 450 
embedding the 3Rs and alternatives in RDT testing is to ensure collaboration between all stakeholders. 451 
Collaboration will speed progress in the refinement of tests and as well as the development of 452 
alternatives. Collaboration across sectors and geographical areas will assist with harmonisation of 453 
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tests and the acceptance of alternatives. Overall, the need for dissemination (see Section 3.7) and 454 
collaboration is seen as being pivotal to identifying the needs, maintaining momentum, and 455 
establishing a community to support delivery of new predictive toxicology methods. 456 
In order to improve, and provide the possibility for the ultimate replacement of, RDT, there is a need 457 
to understand the needs for individual safety decisions which may vary between industry sectors. 458 
Progress will be made, in part at least, by breaking RDT down into component pillars e.g. route of 459 
exposure, target organs, effect etc. Once the components of RDT have been established, suitable 460 
technologies can be identified to replace them. In this context the use of NAMs is ideal to provide 461 
information to assist in the improvement, and ultimate replacement, of RDT. However, the use of 462 
NAMs needs to be properly mapped out onto the needs of RDT in a holistic manner, rather than being 463 
a piecemeal approach.  464 
The use of the information from RDT should also be considered in the development and application 465 
of alternatives. The concept of NGRA, which was initiated by the EPA to develop a new paradigm for 466 
the next generation of risk science (US EPA, 2014; Krewski et al., 2014), is an opportunity to remove 467 
the barrier to acceptance of the tests and to ensure their development is relevant to safety 468 
assessments.  469 
 470 
3.2 Needs Drive the Opportunities – Reasons for Tests Redefined Through Proper Problem 471 
Formulation 472 
There are different, but clearly defined, reasons across the sectors for undertaking a RDT test; some 473 
reasons are common across sectors whilst others may be specific to a regulation. For instance, most, 474 
if not all, sectors require knowledge of PoDs for safety assessment (predominantly from NO(A)ELs) 475 
and it should be considered whether NAMs would (in some instances) provide more relevant PoDs for 476 
the question in hand than a PoD derived from animal testing.  The understanding of the information 477 
required depends on a number of factors especially relating to the protection goals to be achieved, 478 
the decisions to be made, the legal requirements and safety assessment to be met. More emphasis 479 
has to be put on the appropriate level of information that is needed to make the decisions and, more 480 
specifically, the confidence to enable acceptance of the decision and an appreciation of when the 481 
information is incorrect or insufficient. The definition of the issues to be addressed needs to be 482 
considered through better problem formulation. This will assist in the use and understanding 483 
information from alternatives for specific purposes. The information will be context dependent, 484 
despite this there is an opportunity to develop this knowledge across the needs of all sectors. Indeed, 485 
19 
 
within the process of problem formulation, there is the possibility to (re-)define the roles of 486 
alternatives and strategies in their use for RDT more thoroughly.  487 
 488 
3.3 Methodological Development 489 
The cross-sector EPAA Partners’ Forum was in agreement that there are various opportunities for the 490 
development of all areas of RDT methodology from test design  to the reporting of outcomes. The 491 
clear opportunity here is to align new research (and hence funding may be required) for better 492 
problem formulation to support the overall goal of safety to humans. The main areas to be considered 493 
were summarised as being with regard to the information and data derived from RDT and related 494 
studies, the integration of the data to provide a solution and use of appropriate benchmarks to provide 495 
assurance of the outcome.  496 
In terms of the design of RDT various adaptions could be foreseen aligned to the better design of the 497 
test. These could be to take account of preliminary information from e.g. in vitro tests to identify target 498 
organs and effects to investigate. In addition, redesign of the 90-day RDT could allow for the 499 
integration of further measurements into the existing studies to improve the information that was 500 
obtained to support better and more far-sighted analysis. The EMA’s reflection document (EMA, 501 
2018a,b) has identified various opportunities for the implementation of the 3Rs including the 502 
expansion of the concept of integration of additional endpoints in RDT studies.  503 
The EPAA Partners’ Forum heard further positive proposals for refinements that could be made to RDT 504 
tests through integrated and intelligent study design. The aim of such refinements is to combine 505 
multiple endpoints traditionally assessed in separate studies into a single test to provide more 506 
information of high quality and greater relevance, however with the use of fewer animals. Various 507 
opportunities were noted to obtain better information on toxicokinetics, neurotoxicity, 508 
immunotoxicity, in vivo genotoxicity (i.e. integrated micronucleus test) and on MoA.  509 
There are further opportunities to refine the design of RDT studies. One opportunity is to set up tests 510 
to support the derivation of BMD as opposed to NO(A)ELs to obtain the reference dose or PoD. The 511 
design of dosing is currently, in part at least, performed in accordance to regulations i.e. the desire for 512 
hazard characterisation at high doses.  513 
  514 
3.4 Implementation of New Methodologies 515 
The EPAA Partners’ Forum recognised the need for implementation of new technologies, 516 
methodologies and strategies, as well as refinements to existing study types, as a key need and 517 
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opportunity for the 3Rs in RDT. Implementation in this context implies that the new approaches are 518 
suitable and acceptable to make safety decisions relating to RDT. In turn, the EPAA Partners’ Forum 519 
concluded that the new technologies must give the same level of information to support safety 520 
assurance and current RDT studies.  521 
The acceptance of a new approach (in the broadest context) requires some assessment of the 522 
alternative and elements of validation. There is an opportunity and need to move away from the 523 
“standard” methods of validation to a process that is more rapid, responsive and fit for purpose, 524 
bearing in mind that it should also be transferable across sectors and geographies. One clear method 525 
where the usefulness of 3Rs alternatives can be demonstrated (if not formally validated) in RDT is 526 
through the use of well-designed case studies.  527 
Other aspects of implementation include their proper and appropriate use through guidance and 528 
guidelines. Recent advances in topics such as the OECD’s Guidance Document on Good In Vitro 529 
Method Practices (GIVIMP) (OECD, 2018) are important and the process of “good practice” could be 530 
extended to other approaches e.g. in silico techniques. Relating to this, appropriate reporting is 531 
required that is consistent and fit for purpose, as well as being transferable from industry to regulators 532 
and being of an appropriate depth and quality to fulfil regulatory requirements. Many examples exist 533 
of reporting templates and evaluation schemes. Using the example of read-across for regulatory 534 
submission, ECHA has developed the Read-Across Assessment Framework (RAAF) to evaluate the 535 
completeness of a read-across under certain scenarios (ECHA, 2017).  536 
 537 
3.5 Data Sharing 538 
The sharing of data across sectors was seen by the EPAA Partners’ Forum as a very large opportunity 539 
to progress the 3Rs for RDT. There are a number of aspects to this. The first is the sharing of the results 540 
of RDT tests themselves to provide access to more data which would prevent the need for repeat and 541 
unnecessary testing. In addition, a good data source will provide the basis for models as well and the 542 
evaluation and eventual validation of alternatives. The sharing of data should also extend beyond the 543 
standard tests to include data for toxicokinetics, alternatives, omics analyses, mechanistic information 544 
and data from human clinical trials, amongst others. Such an (ambitious) data framework may allow 545 
ultimately for the assurance of no human toxicity from non-clinical data.  546 
Whilst the broadest possible sharing of data was endorsed by the EPAA Partners’ Forum it is 547 
acknowledged that in order for data to be shared there are a number of challenges to be overcome in 548 
terms of the practical aspects, legal ownership and confidential nature of the data. In terms of the 549 
practical storing and sharing of data a number of on-line databases are available including, for 550 
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regulatory purposes, ECHA’s dissemination portal, and to share safety data (e.g. NO(A)ELs) COSMOS 551 
DB – there are also many other databases including commercial ones.  The eTOX Project (Cases et al., 552 
2014; Sanz et al., 2017) has demonstrated the possibilities for sharing data from the pharmaceutical 553 
industry through the development of the eTOX database in the eToxSys platform 554 
(https://www.etoxsys.com/the-database.htm). Many learnings on the extraction, curation and 555 
storage of data from legacy RDT study reports were made in the EU IMI eTOX Project (Cases et al., 556 
2014; Sanz et al., 2017).  557 
The sharing of data would be greatly assisted by the digitalisation of data and use of an appropriate 558 
electronic format – there is a clear opportunity to harmonise data storage to facilitate sharing at 559 
various levels e.g. between industry and the appropriate regulatory agency as well as with other 560 
scientists. As the data matrices become more complex with different types of data, so will the 561 
associated databases. The EU IMI eTransafe Project (http://etransafe.eu/) is attempting to create such 562 
a translational database to support human safety assessment.  Also from the European perspective, 563 
the European Parliament is funding a feasibility project on the joint sharing of data across sectors. The 564 
EU Agencies harmonised approach for safety data access and submission will investigate the possibility 565 
of sharing data between ECHA, EFSA and EMA (European Parliament, 2018).  566 
 567 
3.6 Regulatory Needs 568 
The opportunities to inform regulatory science, regulations and regulators of updates in the 3Rs were 569 
highlighted in the EPAA Partners’ Forum. The motivation here is to bring about and maintain 570 
acceptable change, hence the dialogue with regulators must be open and frank (see Section 3.7 on 571 
Dissemination). A number of opportunities were identified to assist in regulatory science. One of the 572 
key needs of regulatory science must be that it keeps pace with the underlying technology (see Section 573 
1.2). The acceptance of new methods for regulatory purposes is also a fundamental need. The EPAA 574 
Partners’ Forum heard that there are opportunities to facilitate and improve acceptance in a number 575 
of ways. There is a requirement for validation of new methods and there may be opportunities to 576 
streamline the current process to improve the uptake of new methods.  577 
With regard to legislation and regulations, there is an opportunity to increase harmonisation across 578 
global regions and sectors. It is appreciated that different industries will, inevitably, have different 579 
requirements for RDT studies, however, increased harmonisation in areas such as which studies are 580 
required (and any additional testing) should decrease unnecessary repetition of testing. Global 581 
harmonisation of RDT tests and mutual acceptance of data will potentially allow for a significant 582 




A further opportunity is to improve knowledge on RDT for mixtures and natural products. ECHA noted 585 
that approximately two thirds of REACH dossiers were for unknown or variable composition, complex 586 
reaction products or of biological materials (UVCB) substances or mixtures. Currently there is little 587 
known about many of these, other than a small proportion of their constituents. There is, therefore, 588 
an opportunity, to use the existing alternative tests and approaches more efficiently to support 589 
regulatory decision making.  590 
 591 
3.7 Dissemination and Stakeholder Engagement 592 
The EPAA Partners’ Forum recognised the on-going need for dissemination regarding the 3Rs in RDT. 593 
Dissemination is a key opportunity as it will allow for a full dialogue and engagement between all 594 
stakeholders from industry, to the regulatory community across the world, to academics and 595 
businesses that may be developing alternatives. There are several aspects to dissemination with 596 
specific tasks required to raise awareness in the developers of alternatives to RDT studies as well as 597 
how they may be validated (e.g. through EURL ECVAM), implemented and accepted. Conversely 598 
regulators need to be informed of the new technologies and improvements and / or refinements in 599 
standard tests that may be occurring. Lastly, the users of existing and new alternatives for RDT, e.g. in 600 
industry, need to be made aware of the utility and possible acceptance of such approaches. 601 
 602 
3.8 Capacity Building and Training in the 3Rs 603 
The increased need for expertise in all areas of safety assessment related to RDT was confirmed by 604 
the EPAA Partners’ Forum. Capacity building has the opportunity of increasing the number of trained 605 
toxicologists and safety assessors who can implement the 3Rs whilst assuring the same level of 606 
confidence on the outcome. A key aspect of capacity building is through training of new and existing 607 
scientists which will enable them to understand and utilise the new technologies as well as to refine 608 
the existing tests for RDT.  609 
 610 
4. Current Culture of Synergy and Optimisation of 3Rs for RDT 611 
Sections 2 and 3 indicated that many current, and future, opportunities for synergies and optimisation 612 
in the 3Rs for RDT were identified in the EPAA Partners’ Forum. In addition, an encouraging culture of 613 
many types of synergies, bringing together regulatory agencies and stakeholders, was evident with 614 
23 
 
clear motivation for on-going progress. This section details some of the main synergies that are 615 
occurring to make progress in the 3Rs for RDT that are not described above.  616 
A key focus of synergies between stakeholders is to enable and encourage collaboration and the 617 
development of a continuous dialogue in areas such as the development of the full range of 618 
alternatives to the standard RDT tests (i.e. in silico, in vitro, omics etc.), the implementation and 619 
acceptance of alternatives, and the development of IATA, strategies and workflows for safety 620 
assessments. Synergies for the promotion and optimisation of 3Rs approaches usually start within an 621 
organisation (especially when it is large) and spread outwards. The EPAA itself is based on 622 
collaboration between different industry sectors and regulators and aims at identifying and fostering 623 
effective synergies among its members.  624 
One area where there is scope for greater synergy, but less evidence of actual progress, is cross-sector 625 
collaboration in research projects i.e. different industrial sectors working together. Therefore, the 626 
EPAA Partners’ Forum has been designed as an opportunity to facilitate this. Cross-sector synergies 627 
offer many opportunities for the 3Rs, e.g. the EMA (EMA, 2018a,b) and others have suggested the 628 
integration of further endpoints in a more intelligent design of tests and the increased use of NAMs 629 
to provide better information – all of these and other proposals could have significant positive impact 630 
on other sectors. The EPAA Partners’ Forum discussed more ways of encouraging and implementing 631 
synergies in the 3Rs for RDT. One method is the use of case studies with input from all partners. 632 
Another valid approach to developing synergies for the 3Rs in RDT is to address a specific problem or 633 
issue, such as a joint EU and US project on the identification of the most sensitive organ in RDT.  634 
 635 
5. Summary and Conclusions  636 
The EPAA Partners’ Forum on RDT testing aimed to identify synergies between sectors and 637 
opportunities to progress these in existing research frameworks. The EPAA Partners Forum heard that, 638 
with the exception of the cosmetics sector, RDT testing on animals is still a regulatory requirement 639 
across all industries. It is done to comply with legislation/regulations as well as to provide a rich source 640 
of information from which to perform safety assessments. A variety of tests are performed, with tests 641 
such as the 90-day rodent assays being viewed as valuable, and often essential, to assist in the 642 
identification of sub-chronic, organ-level adverse effects.  643 
Immediate replacement of tests for RDT across all sectors is unlikely due to the complexity of the 644 
knowledge they provide about the test substance. The level of information obtained is often seen as 645 
extremely valuable and necessary to make safety assessment decisions following long-term, low dose 646 
exposure. It is acknowledged that a direct one-to-one replacement of the 90-day RDT test by a single 647 
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assay, even at the organ level, is not possible. However, despite the difficulty in finding non-animal 648 
approaches to allow safety decisions to be made about systemic toxicity, there has been much effort 649 
at the basic research level with significant funding from the EU’s historical Framework Programmes 650 
and current H2020 Programme, in addition to efforts elsewhere on the globe. The EPAA Partners 651 
Forum was able to appreciate that real opportunities for the 3Rs in RDT testing will come from a 652 
combination of problem formulation, better study design (including dose level selection) and the use 653 
of NAMs, AOPs and other targeted MoA testing that may be needed to improve hazard identification 654 
and risk assessment. 655 
Read-across of effects between “similar” molecules is one paradigm that was reported to provide 656 
information to support risk assessment following repeated exposure. Currently there is much debate 657 
about how, and if, read-across can provide information to allow safety decisions to be made about 658 
RDT in a regulatory context. One proposed solution is to support read-across through a body of 659 
evidence supplemented by data from NAMs. Other approaches to making safety decisions for 660 
repeated exposure relate to the development and use of various testing strategies and workflows 661 
integrating various types of data. Whilst the workflows are distinct for different applications, in 662 
practice there are commonalities between them including the use of exposure information, read-663 
across or in silico predictions as well as other data from NAMs. They are generally designed to enable 664 
decision making from minimum experimental outlay. The workflows and schemes for safety 665 
assessment often include an early element relating to exposure e.g. the use of TTC or other exposure-666 
based waiving.  667 
Clear opportunities for synergies across stakeholders were identified at the EPAA Partners’ Forum. For 668 
instance, the lack of harmonisation of regulations within and between sectors and geographical areas 669 
could be addressed. In addition, there is a recognised need to develop the 90-day RDT test further to 670 
provide more and better information, e.g. better dosing regimes and the increased use of omics or 671 
other NAMs to identify additional testing and / or analysis needed to support, for example, the 672 
assessment of neurotoxicity or endocrine disruption. Non-animal (in silico and in vitro) alternative 673 
approaches are being developed, however, it was appreciated that regulatory science need to keep 674 
pace with the rapid changes and improvements in technology to allow for their implementation. 675 
As an outcome of the EPAA Partners' Forum on repeated dose toxicity testing, the following 676 
conclusions were made: 677 
- Applying alternative methods when assessing systemic toxicity is a major challenge due to the 678 
complexity of interactions in the living body and for certain industries (e.g. cosmetics) this is 679 
critical due to regulatory requirements; 680 
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- Although EPAA partners are committed to the 3Rs, it was recognised that up until now animal 681 
tests on systemic toxicity are pivotal for supporting many safety decisions; 682 
- Given the comprehensive data set provided by the traditional animal RDT testing, the full 683 
replacement with alternatives represents a major challenge. Breaking down the questions 684 
addressed by RDT (e.g. POD, identification of target organs) is required to make progress; 685 
- Any replacement effort requires close cooperation amongst all safety assessors (in industry, 686 
regulatory agencies, academia) at a very early stage during alternative method design and 687 
development, ideally at a global scale; 688 
- EPAA is well placed to enable cross-fertilisation, help set future research agendas and convene 689 
key players; 690 
- EPAA facilitates sharing of case studies where novel approaches to safety decision making 691 
have been used successfully. 692 
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